5-acetyl-5,6,11,12-tetrahydro-8-bromo-dibenz[b,f]-azocine | 864750-03-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 5-acetyl-5,6,11,12-tetrahydro-8-bromo-dibenz[b,f]-azocine
• 英文别名: 5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenz[b,f]azocine；1-(8-bromo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)-ethanone；1-(8-bromo-11,12-dihydro-6H-benzo[c][1]benzazocin-5-yl)ethanone
• CAS: 864750-03-8
• 化学式: C₁₇H₁₆BrNO
• 分子量: 330.224
• InChiKey: IWZPMVGKGUWIMO-UHFFFAOYSA-N

物化性质

• 沸点：
  494.2±45.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-acetyl-5,6,11,12-tetrahydro-8-bromo-dibenz[b,f]-azocine 、 2-甲氧基苯基硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 2.0h， 以62%的产率得到5-acetyl-5,6,11,12-tetrahydro-8-(2-methoxyphenyl)-dibenzo[b,f]azocine
  参考文献：
  名称：

  Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

  摘要：

  融合三环化合物，使用这种化合物治疗激素敏感性疾病如前列腺癌的方法，以及含有这种化合物的药物组合物。

  公开号：

  US20050250753A1
• 作为产物：
  描述：

  6-溴茚酮 在 Rh on carbon 盐酸 、 dimethyl sulfide borane 、 硫酸 、 氢气 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 5-acetyl-5,6,11,12-tetrahydro-8-bromo-dibenz[b,f]-azocine
  参考文献：
  名称：

  Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3

  摘要：

  A novel series of 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitors has been identified. These inhibitors, based on a dibenzazocine core, exhibited picomolar to low nanomolar inhibition of 17 beta-HSD3 in cell-free enzymatic as well as in cell-based transcriptional reporter assays. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.039

文献信息

• Synthesis of a Human Urate Transporter-1 Inhibitor, an Arginine Vasopressin Antagonist, and a 17β-Hydroxysteroid Dehydrogenase Type-3 Inhibitor, Using Ring-Expansion of Cyclic Ketoximes with DIBALH
  作者：Hidetsura Cho、Yusuke Iwama、Kentaro Okano、Hidetoshi Tokuyama

  DOI：10.1248/cpb.c13-00961

  日期：——

  dehydrogenase type-3 inhibitor, is described. These compounds were synthesized via construction of their 3,4-dihydro-2H-benzo[b][1,4]oxazine, dibenzodiazepine, and dibenzazocine skeletons, respectively, using the reductive ring-expansion reaction of the corresponding bicyclic or tricyclic oximes with diisobutylaluminum hydride.

  描述了三种临床候选药物的合成：人尿酸盐转运蛋白-1抑制剂，精氨酸加压素拮抗剂和17β-羟基类固醇脱氢酶3型抑制剂。使用相应的双环或三环肟的还原环扩环反应，分别通过构建3,4-二氢-2H-苯并[b] [1,4]恶嗪，二苯并二氮杂卓和二苯甲唑嗪骨架来合成这些化合物。二异丁基氢化铝。
• Construction of Dibenzazocine Skeleton by Regiocontrolled Ring-Expansion Reaction of Cyclic Oxime with DIBAL-H: Facile Synthesis of 17β-Hydroxy­steroid Dehydrogenase Type 3 Inhibitor
  作者：Hidetsura Cho、Hidetoshi Tokuyama、Yusuke Iwama、Kentaro Okano

  DOI：10.1055/s-0032-1318489

  日期：——

  Synthetic studies on a 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitor are described. The unsymmetrical dibenzazocine skeleton was constructed by a regiocontrolled ring-expansion reaction of a cyclic oxime with DIBAL-H.
• US7417040B2
  申请人：——

  公开号：US7417040B2

  公开（公告）日：2008-08-26
• Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3
  作者：Brian E. Fink、Ashvinikumar V. Gavai、John S. Tokarski、Bindu Goyal、Raj Misra、Hai-Yun Xiao、S. David Kimball、Wen-Ching Han、Derek Norris、Thomas E. Spires、Dan You、Marco M. Gottardis、Matthew V. Lorenzi、Gregory D. Vite

  DOI：10.1016/j.bmcl.2005.12.039

  日期：2006.3

  A novel series of 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitors has been identified. These inhibitors, based on a dibenzazocine core, exhibited picomolar to low nanomolar inhibition of 17 beta-HSD3 in cell-free enzymatic as well as in cell-based transcriptional reporter assays. (C) 2005 Elsevier Ltd. All rights reserved.
• Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
  申请人：Fink E. Brian

  公开号：US20050250753A1

  公开（公告）日：2005-11-10

  Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

  融合三环化合物，使用这种化合物治疗激素敏感性疾病如前列腺癌的方法，以及含有这种化合物的药物组合物。